{"transactions":[{"id":2590901,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-25T23:42:33.000Z","date":"2021-08-25","kind":"sale","acquired":false,"shares":1713,"price":29.09,"value":49831.17,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.01 to $29.47 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7805483,"source":{"system":"sec-edgar","filing":"0001209191-21-053380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121053380/doc4.xml","form_type":"4"}},{"id":2590900,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-25T23:42:33.000Z","date":"2021-08-24","kind":"sale","acquired":false,"shares":50822,"price":29.48,"value":1498232.56,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.15 to $29.715 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7807196,"source":{"system":"sec-edgar","filing":"0001209191-21-053380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121053380/doc4.xml","form_type":"4"}},{"id":2590899,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-25T23:42:33.000Z","date":"2021-08-23","kind":"sale","acquired":false,"shares":53359,"price":29.11,"value":1553280.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.41 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7858018,"source":{"system":"sec-edgar","filing":"0001209191-21-053380","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121053380/doc4.xml","form_type":"4"}},{"id":2605494,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-08-12T20:55:17.000Z","date":"2021-08-11","kind":"sale","acquired":false,"shares":2510,"price":29.05,"value":72915.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on June 23, 2021."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.00 to $29.13 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7911377,"source":{"system":"sec-edgar","filing":"0001209191-21-051148","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919121051148/doc4.xml","form_type":"4"}},{"id":2687158,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T22:09:39.000Z","date":"2021-06-02","kind":"sale","acquired":false,"shares":25118,"price":20.5,"value":514919.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F13","text":"The shares were sold as follows: 22,078 by UBS Oncology and 3,040 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.24 to $20.76 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 225,445 by AM LLC and 3,196,707 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6328095,"source":{"system":"sec-edgar","filing":"0001209191-21-037379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121037379/doc4.xml","form_type":"4"}},{"id":2687157,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T22:09:39.000Z","date":"2021-06-01","kind":"sale","acquired":false,"shares":18491,"price":20.44,"value":377956.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F10","text":"The shares were sold as follows: 16,253 by UBS Oncology and 2,238 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 228,485 by AM LLC and 3,218,785 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6353213,"source":{"system":"sec-edgar","filing":"0001209191-21-037379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121037379/doc4.xml","form_type":"4"}},{"id":2687156,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T22:09:39.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":100,"price":22.6,"value":2260.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,723 by AM LLC and 3,235,038 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6371704,"source":{"system":"sec-edgar","filing":"0001209191-21-037379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121037379/doc4.xml","form_type":"4"}},{"id":2687155,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T22:09:39.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":3100,"price":21.92,"value":67952.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  2,725 by UBS Oncology and 375 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.58 to $22.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 230,735 by AM LLC and 3,235,126 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6371804,"source":{"system":"sec-edgar","filing":"0001209191-21-037379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121037379/doc4.xml","form_type":"4"}},{"id":2687154,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T22:09:39.000Z","date":"2021-05-28","kind":"sale","acquired":false,"shares":10685,"price":20.88,"value":223102.8,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 9,392 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 1,293 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.50  inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 231,110 by AM LLC and 3,237,851 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6374904,"source":{"system":"sec-edgar","filing":"0001209191-21-037379","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121037379/doc4.xml","form_type":"4"}},{"id":2693808,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T23:40:41.000Z","date":"2021-05-27","kind":"sale","acquired":false,"shares":13961,"price":20.26,"value":282849.86,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  12,271 by UBS Oncology and 1,690  by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.05 to $20.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 232,403 by AM LLC and 3,247,243 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6385589,"source":{"system":"sec-edgar","filing":"0001209191-21-036349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121036349/doc4.xml","form_type":"4"}},{"id":2693807,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-27T23:40:41.000Z","date":"2021-05-26","kind":"sale","acquired":false,"shares":3198,"price":20.04,"value":64087.92,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 2,811 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 387 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 234,093 by AM LLC and 3,259,514 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6399550,"source":{"system":"sec-edgar","filing":"0001209191-21-036349","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121036349/doc4.xml","form_type":"4"}},{"id":2699337,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T00:11:52.000Z","date":"2021-05-24","kind":"sale","acquired":false,"shares":5000,"price":20.12,"value":100600.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  4,395 by UBS Oncology and 605 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.355 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 234,480 by AM LLC and 3,262,325 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6402748,"source":{"system":"sec-edgar","filing":"0001209191-21-035558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121035558/doc4.xml","form_type":"4"}},{"id":2699336,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-25T00:11:52.000Z","date":"2021-05-21","kind":"sale","acquired":false,"shares":10907,"price":20.21,"value":220430.47,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 9,587 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 1,320 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 235,085 by AM LLC and 3,266,720 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6407748,"source":{"system":"sec-edgar","filing":"0001209191-21-035558","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121035558/doc4.xml","form_type":"4"}},{"id":2703574,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-20T23:20:37.000Z","date":"2021-05-20","kind":"sale","acquired":false,"shares":11713,"price":20.34,"value":238242.42,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 10,295 by UBS Oncology and 1,418 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.07 to $20.84 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 236,405 by AM LLC and 3,276,307 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6418655,"source":{"system":"sec-edgar","filing":"0001209191-21-034626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121034626/doc4.xml","form_type":"4"}},{"id":2703573,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-20T23:20:37.000Z","date":"2021-05-19","kind":"sale","acquired":false,"shares":17833,"price":20.39,"value":363614.87,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  15,675 by UBS Oncology and 2,158 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 237,823 by AM LLC and 3,286,602 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6430368,"source":{"system":"sec-edgar","filing":"0001209191-21-034626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121034626/doc4.xml","form_type":"4"}},{"id":2703572,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-20T23:20:37.000Z","date":"2021-05-18","kind":"sale","acquired":false,"shares":18402,"price":20.67,"value":380369.34,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 16,175 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 2,227 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.26 to $20.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 239,981 by AM LLC and 3,302,277 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6448201,"source":{"system":"sec-edgar","filing":"0001209191-21-034626","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121034626/doc4.xml","form_type":"4"}},{"id":2710602,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T21:23:41.000Z","date":"2021-05-17","kind":"sale","acquired":false,"shares":4666,"price":20.07,"value":93646.62,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 4,101 by UBS Oncology and 565 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.435 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 242,208 by AM LLC and 3,318,452 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6466603,"source":{"system":"sec-edgar","filing":"0001209191-21-033213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121033213/doc4.xml","form_type":"4"}},{"id":2710601,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T21:23:41.000Z","date":"2021-05-14","kind":"sale","acquired":false,"shares":6900,"price":20.04,"value":138276.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  6,065 by UBS Oncology and 835 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.96 to $20.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 242,773 by AM LLC and 3,322,553 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6471269,"source":{"system":"sec-edgar","filing":"0001209191-21-033213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121033213/doc4.xml","form_type":"4"}},{"id":2710600,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-17T21:23:41.000Z","date":"2021-05-13","kind":"sale","acquired":false,"shares":4855,"price":20.06,"value":97391.3,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 4,267 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 588 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.95 to $20.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 243,608 by AM LLC and 3,328,618 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6478169,"source":{"system":"sec-edgar","filing":"0001209191-21-033213","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121033213/doc4.xml","form_type":"4"}},{"id":2716863,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T22:09:04.000Z","date":"2021-05-12","kind":"sale","acquired":false,"shares":29684,"price":20.53,"value":609412.52,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 26,092 by UBS Oncology and 3,592 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.845 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 244,196 by AM LLC and 3,332,885 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6483024,"source":{"system":"sec-edgar","filing":"0001209191-21-032178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121032178/doc4.xml","form_type":"4"}},{"id":2716862,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T22:09:04.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":7672,"price":21.51,"value":165024.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 6,744 by UBS Oncology and 928 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.38 to $21.73 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 247,788 by AM LLC and 3,358,977 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6512708,"source":{"system":"sec-edgar","filing":"0001209191-21-032178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121032178/doc4.xml","form_type":"4"}},{"id":2716861,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T22:09:04.000Z","date":"2021-05-11","kind":"sale","acquired":false,"shares":13773,"price":20.96,"value":288682.08,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 12,106 by UBS Oncology and 1,667 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.38 to $21.375 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 248,716 by AM LLC and 3,365,721 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6520380,"source":{"system":"sec-edgar","filing":"0001209191-21-032178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121032178/doc4.xml","form_type":"4"}},{"id":2716860,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T22:09:04.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":411,"price":22.46,"value":9231.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  361 by UBS Oncology and 50 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.22 to $22.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 250,383 by AM LLC and 3,377,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6534153,"source":{"system":"sec-edgar","filing":"0001209191-21-032178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121032178/doc4.xml","form_type":"4"}},{"id":2716859,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-12T22:09:04.000Z","date":"2021-05-10","kind":"sale","acquired":false,"shares":16722,"price":21.78,"value":364205.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 14,698 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 2,024 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.16 to $22.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 250,433 by AM LLC and 3,378,188 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6534564,"source":{"system":"sec-edgar","filing":"0001209191-21-032178","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121032178/doc4.xml","form_type":"4"}},{"id":2725321,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":12899925,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F9","text":"The shares were held as follows: 693,667 by BV 2014, 46,266 by BV 2014(B), 23,876 by AM BV2014, 152,083 by MPM OIF and 572,141 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"No securities held by the Reporting Persons."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1488033},"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725320,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":false,"shares":38817998,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F7","text":"The shares were held as follows: 2,087,358 by BV 2014, 139,224 by BV 2014(B), 71,848 by AM BV2014, 457,643 by MPM OIF and 1,721,669 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"No securities held by the Reporting Persons."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4477742},"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725319,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"purchase","acquired":true,"shares":245000,"price":16,"value":3920000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were purchased as follows: 114,210 by BV 2014, 7,618 by BV 2014(B), 3,931 by AM BV2014, 25,040 by MPM OIF and 94,201 by UBS Oncology."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 461,408 by AM LLC, 2,895,235 by BV 2014, 193,108 by BV 2014(B), 99,655 by AM BV2014, 634,766 by MPM OIF and 2,388,011 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6672183,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725318,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":1488033,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 461,408 by AM LLC, 2,781,025 by BV 2014, 185,490 by BV 2014(B), 95,724 by AM BV2014, 609,726 by MPM OIF and 2,293,810 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6427183,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725317,"issuer":{"id":7244,"kind":"organization","name":"Werewolf Therapeutics, Inc."},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69398,"kind":"organization","name":"MPM ONCOLOGY INNOVATIONS FUND LP","position":2,"cik":"0001719960","reported_name":"MPM ONCOLOGY INNOVATIONS FUND LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":3,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":5,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":69399,"kind":"organization","name":"MPM Oncology Innovations Fund GP LLC","position":6,"cik":"0001857903","reported_name":"MPM Oncology Innovations Fund GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":7,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:19:54.000Z","date":"2021-05-04","kind":"exercise","acquired":true,"shares":4477742,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A Preferred Stock and Series B Preferred Stock converted into common stock on a 8.6691-for-1 basis into the number of shares of common stock shown in Column 7 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The shares are held as follows: 461,408 by MPM Asset Management LLC (\"AM LLC\"), 2,087,358 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 139,224 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 71,848 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 457,643 by MPM Oncology Innovations Fund, L.P. (\"MPM OIF\") and 1,721,669 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadicke is a member of AM LLC and a Managing Director of BV LLC. MPM Oncology Innovations Fund GP LLC (\"MPM OIF GP\") is the general partner of MPM OIF."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P.  Ansbert Gadicke is the managing director of Oncology GP LLC.  Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":4939150,"source":{"system":"sec-edgar","filing":"0001209191-21-030625","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030625/doc4.xml","form_type":"4"}},{"id":2725314,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:05:43.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":59,"price":23.09,"value":1362.31,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  52 by UBS Oncology and 7 by AM LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 252,457 by AM LLC and 3,392,886 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6551286,"source":{"system":"sec-edgar","filing":"0001209191-21-030611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030611/doc4.xml","form_type":"4"}},{"id":2725313,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-06T20:05:43.000Z","date":"2021-05-05","kind":"sale","acquired":false,"shares":10113,"price":22.52,"value":227744.76,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  8,889 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 1,224 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.075 to $23.02 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 252,464 by AM LLC and 3,392,938 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6551345,"source":{"system":"sec-edgar","filing":"0001209191-21-030611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121030611/doc4.xml","form_type":"4"}},{"id":2730805,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T21:43:55.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":3500,"price":23.33,"value":81655.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 3,076 by UBS Oncology and 424 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.29 to $23.40 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 253,688 by AM LLC and 3,401,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6561458,"source":{"system":"sec-edgar","filing":"0001209191-21-029994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029994/doc4.xml","form_type":"4"}},{"id":2730804,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T21:43:55.000Z","date":"2021-05-04","kind":"sale","acquired":false,"shares":26230,"price":23.03,"value":604076.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 23,056 by UBS Oncology and 3,174 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.29 to $23.27 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 254,112 by AM LLC and 3,404,903 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6564958,"source":{"system":"sec-edgar","filing":"0001209191-21-029994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029994/doc4.xml","form_type":"4"}},{"id":2730803,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T21:43:55.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":4401,"price":23.45,"value":103203.45,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 3,868 by UBS Oncology and 533 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.38 to $23.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 257,286 by AM LLC and 3,427,959 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6591188,"source":{"system":"sec-edgar","filing":"0001209191-21-029994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029994/doc4.xml","form_type":"4"}},{"id":2730802,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T21:43:55.000Z","date":"2021-05-03","kind":"sale","acquired":false,"shares":26365,"price":23.03,"value":607185.95,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  23,175 by UBS Oncology and 3,190 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.37 to $23.35 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 257,819 by AM LLC and 3,431,827 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6595589,"source":{"system":"sec-edgar","filing":"0001209191-21-029994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029994/doc4.xml","form_type":"4"}},{"id":2730801,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-05-04T21:43:55.000Z","date":"2021-04-30","kind":"sale","acquired":false,"shares":268023,"price":22.35,"value":5990314.05,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  235,586 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 32,437 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.825 to $22.63 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 261,009 by AM LLC and 3,455,002 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6621954,"source":{"system":"sec-edgar","filing":"0001209191-21-029994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029994/doc4.xml","form_type":"4"}},{"id":2736166,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-29","kind":"sale","acquired":false,"shares":21781,"price":22.54,"value":490943.74,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F17","text":"The shares were sold as follows: 19,145 by UBS Oncology and 2,636 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.36 to $22.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 293,446 by AM LLC and 3,690,588 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6889977,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2736165,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-29","kind":"sale","acquired":false,"shares":45511,"price":22.02,"value":1002152.22,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 40,003 by UBS Oncology and 5,508 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.32 to $22.31 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 296,082 by AM LLC and 3,709,733 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6911758,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2736164,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-28","kind":"sale","acquired":false,"shares":36803,"price":22.01,"value":810034.03,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 32,349 by UBS Oncology and 4,454 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.93 to $22.155 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 301,590 by AM LLC and 3,749,736 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6957269,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2736163,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-28","kind":"sale","acquired":false,"shares":14219,"price":21.64,"value":307699.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 12,498 by UBS Oncology and 1,721 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.92 to $21.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 306,044 by AM LLC and 3,782,085 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":6994072,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2736162,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":8328,"price":21.26,"value":177053.28,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  7,320 by UBS Oncology and 1,008 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.08 to $21.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 307,765 by AM LLC and 3,794,583 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7008291,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2736161,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-29T21:46:23.000Z","date":"2021-04-27","kind":"sale","acquired":false,"shares":3501,"price":20.99,"value":73485.99,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  3,077 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 424 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.08 to $21.07 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 308,773 by AM LLC and 3,801,903 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7016619,"source":{"system":"sec-edgar","filing":"0001209191-21-029064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121029064/doc4.xml","form_type":"4"}},{"id":2742173,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T20:04:14.000Z","date":"2021-04-21","kind":"sale","acquired":false,"shares":555,"price":19.48,"value":10811.4,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  488 by UBS Oncology and 67 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.40 to $19.57 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 309,197 by AM LLC and 3,804,980 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7020120,"source":{"system":"sec-edgar","filing":"0001209191-21-027939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027939/doc4.xml","form_type":"4"}},{"id":2742172,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-22T20:04:14.000Z","date":"2021-04-21","kind":"sale","acquired":false,"shares":8417,"price":18.94,"value":159417.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  7,398 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 1,019 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.40 to $19.33 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 309,264 by AM LLC and 3,805,468 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7020675,"source":{"system":"sec-edgar","filing":"0001209191-21-027939","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027939/doc4.xml","form_type":"4"}},{"id":2744189,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":834,"price":19.09,"value":15921.06,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 733 by UBS Oncology and 101 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.03 to $19.15 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,283 by AM LLC and 3,812,866 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7029092,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2744188,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-20","kind":"sale","acquired":false,"shares":21415,"price":18.7,"value":400460.5,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 18,823 by UBS Oncology and 2,592 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.03 to $19.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 310,384 by AM LLC and 3,813,599 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7029926,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2744187,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":100,"price":20.08,"value":2008.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F10","text":"The shares were sold as follows: 88 by UBS Oncology and 12 by AM LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,976 by AM LLC and 3,832,422 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7051341,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2744186,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-19","kind":"sale","acquired":false,"shares":9956,"price":19.29,"value":192051.24,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F7","text":"The shares were sold as follows: 8,751 by UBS Oncology and 1,205 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.00 to $19.83 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 312,988  by AM LLC and 3,832,510 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7051441,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2744185,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":300,"price":20.56,"value":6168.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  264 by UBS Oncology and 36 by AM LLC."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 314,193 by AM LLC and 3,841,261 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7061397,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2744184,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-20T22:07:10.000Z","date":"2021-04-16","kind":"sale","acquired":false,"shares":5547,"price":19.82,"value":109941.54,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  4,875 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 672 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.41 to $20.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 314,229 by AM LLC and 3,841,525 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7061697,"source":{"system":"sec-edgar","filing":"0001209191-21-027611","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121027611/doc4.xml","form_type":"4"}},{"id":2748746,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T00:00:20.000Z","date":"2021-04-15","kind":"sale","acquired":false,"shares":8696,"price":20.49,"value":178181.04,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F14","text":"The shares were sold as follows: 7,644 by UBS Oncology and 1,052 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F15","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.15 to $20.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 314,901 by AM LLC and 3,846,400 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7067244,"source":{"system":"sec-edgar","filing":"0001209191-21-026880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026880/doc4.xml","form_type":"4"}},{"id":2748745,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T00:00:20.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":12806,"price":20.83,"value":266748.98,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F11","text":"The shares were sold as follows: 11,256 by UBS Oncology and 1,550 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.18 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F13","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 315,953 by AM LLC and 3,854,044 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7075940,"source":{"system":"sec-edgar","filing":"0001209191-21-026880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026880/doc4.xml","form_type":"4"}},{"id":2748744,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T00:00:20.000Z","date":"2021-04-14","kind":"sale","acquired":false,"shares":1000,"price":20.06,"value":20060.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F8","text":"The shares were sold as follows: 879 by UBS Oncology and 121 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.44 to $20.39 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 317,503  by AM LLC and 3,865,300 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7088746,"source":{"system":"sec-edgar","filing":"0001209191-21-026880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026880/doc4.xml","form_type":"4"}},{"id":2748743,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T00:00:20.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":2362,"price":20.08,"value":47428.96,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F5","text":"The shares were sold as follows:  2,076 by UBS Oncology and 286 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.89 to $20.50 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 317,624 by AM LLC and 3,866,179 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7089746,"source":{"system":"sec-edgar","filing":"0001209191-21-026880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026880/doc4.xml","form_type":"4"}},{"id":2748742,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-16T00:00:20.000Z","date":"2021-04-13","kind":"sale","acquired":false,"shares":13692,"price":19.35,"value":264940.2,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  12,035 by UBS Oncology Impact Fund, L.P. (\"UBS Oncology\") and 1,657 by MPM Asset Management LLC (\"AM LLC\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.89 to $19.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 317,910 by AM LLC and 3,868,255 by UBS Oncology.  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7092108,"source":{"system":"sec-edgar","filing":"0001209191-21-026880","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026880/doc4.xml","form_type":"4"}},{"id":2750626,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:15:02.000Z","date":"2021-04-09","kind":"sale","acquired":false,"shares":200,"price":29.99,"value":5998.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 71 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 2 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 45 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 1by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 81 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,068,870 by BV 2014, 128,561 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 71,210 by AM BV2014, 1,306,654 by BV 2018, 64,705 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 25,787 by AM BV2018 and 2,338,581 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6004368,"source":{"system":"sec-edgar","filing":"0001209191-21-026433","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026433/doc4.xml","form_type":"4"}},{"id":2750625,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:13:25.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":400,"price":22.68,"value":9072.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F12","text":"The shares were sold as follows: 352 by UBS Oncology and 48 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.63 to $22.72 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 319,567 by AM LLC and 3,880,290 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7105800,"source":{"system":"sec-edgar","filing":"0001209191-21-026431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026431/doc4.xml","form_type":"4"}},{"id":2750624,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:13:25.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":6700,"price":21.52,"value":144184.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 5,889 by UBS Oncology and 811 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.25 to $22.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 319,615 by AM LLC and 3,880,642 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7106200,"source":{"system":"sec-edgar","filing":"0001209191-21-026431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026431/doc4.xml","form_type":"4"}},{"id":2750623,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:13:25.000Z","date":"2021-04-12","kind":"sale","acquired":false,"shares":13528,"price":20.72,"value":280300.16,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/16/2021."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows:  11,891 by UBS Oncology and 1,637 by AM LLC."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.25 to $21.24 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by BV 2014(B), 96,376 by AM BV2014, 320,426 by AM LLC and 3,886,531 by UBS Oncology. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7112900,"source":{"system":"sec-edgar","filing":"0001209191-21-026431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026431/doc4.xml","form_type":"4"}},{"id":2750622,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":4,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":5,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-13T20:13:25.000Z","date":"2021-04-09","kind":"sale","acquired":false,"shares":10300,"price":23.67,"value":243801.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 12/21/2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows:  9,939 by MPM BioVentures 2014, L.P. (\"BV 2014\") and 361 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\")."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.45 to $24.20 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The shares are held as follows: 2,657,097 by BV 2014, 152,470 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 96,376 by AM BV2014, 322,063 by MPM Asset Management LLC (\"AM LLC\") and 3,898,422 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\").  MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. BV LLC is the manager of AM BV2014. Messrs. Evnin, Gadicke and Foley are the members of BV LLC and Messrs. Evnin and Gadicke are the members of AM LLC. Mr. Gadicke is the Managing Member of Oncology GP LLC. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein."}],"balance_after":7126428,"source":{"system":"sec-edgar","filing":"0001209191-21-026431","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026431/doc4.xml","form_type":"4"}},{"id":2752248,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":414,"price":31.01,"value":12838.14,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F18","text":"The shares were sold as follows: 147 by BV 2014, 5 by AM BV2014, 93 by BV 2018, 2 by AM BV2018 and 167 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.945 to $31.19 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"The shares are held as follows: 2,068,941 by BV 2014, 128,561 by BV 2014(B), 71,212 by AM BV2014, 1,306,699 by BV 2018, 64,705 by BV 2018(B), 25,788 by AM BV2018 and 2,338,662 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6004568,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2752247,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-08","kind":"sale","acquired":false,"shares":31890,"price":30.51,"value":972963.9,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F15","text":"The shares were sold as follows: 11,354 by BV 2014, 391 by AM BV2014, 7,171 by BV 2018, 141 by AM BV2018 and 12,833 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.95 to $30.92 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"The shares are held as follows: 2,069,088 by BV 2014, 128,561 by BV 2014(B), 71,217 by AM BV2014, 1,306,792 by BV 2018, 64,705 by BV 2018(B), 25,790 by AM BV2018 and 2,338,829 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6004982,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2752246,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-07","kind":"other","acquired":false,"shares":15670,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F12","text":"Represents a pro rata in-kind distribution from BV 2014(B) and BV 2018(B) to its respectve limited partners for no consideration."},{"field":"shares","element":"transactionShares","label":"F13","text":"The shares were distributed as follows:  10,424 shares by BV 2014(B) and 5,246 shares by BV 2018(B)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are held as follows: 2,080,442 by BV 2014, 128,561 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 64,705 by BV 2018(B), 25,931 by AM BV2018 and 2,351,662 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6036872,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2752245,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":1300,"price":33.84,"value":43992.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F9","text":"The shares were sold as follows: 463 by BV 2014, 16 by AM BV2014, 292 by  BV 2018, 6 by AM BV2018 and 523 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.50 to $34.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are held as follows: 2,080,442 by BV 2014, 138,985 by BV 2014(B), 71,608 by AM BV2014, 1,313,963 by BV 2018, 69,951 by BV 2018(B), 25,931 by AM BV2018 and 2,351,662 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6052542,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2752244,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":3083,"price":32.84,"value":101245.72,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F6","text":"The shares were sold as follows: 1,097 by BV 2014, 38 by AM BV2014, 693 by  BV 2018, 14 by AM BV2018 and 1,241 by UBS Oncology."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.50 to $33.265 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"The shares are held as follows: 2,080,905 by BV 2014, 138,985 by BV 2014(B), 71,624 by AM BV2014, 1,314,255 by BV 2018, 69,951 by BV 2018(B), 25,937 by AM BV2018 and 2,352,185 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6053842,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2752243,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":3,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":4,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":5,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-04-09T20:47:12.000Z","date":"2021-04-07","kind":"sale","acquired":false,"shares":5295,"price":32.07,"value":169810.65,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction effected pursuant to a plan established pursuant to Rule 10b5-1."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares were sold as follows: 1,885 by MPM BioVentures 2014, L.P. (\"BV 2014\"), 65 by MPM Asset Management Investors BV2014 LLC (\"AM BV2014\"), 1,191 by MPM BioVentures 2018, L.P. (\"BV 2018\"), 23 by MPM Asset Management Investors BV2018 LLC (\"AM BV2018\") and 2,131 by UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC (\"BV 2014 LLC\") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV 2014 LLC is the manager of AM BV2014. MPM BioVentures 2018 GP LLC and MPM BioVentures 2018 LLC (\"BV 2018 LLC\") are the direct and indirect general partners of BV 2018 and BV 2018(B). BV 2018 LLC is the manager of AM BV2018. Ansbert Gadicke is a managing director of BV 2014 LLC and BV 2018 LLC."},{"field":"shares","element":"transactionShares","label":"F3","text":"MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadicke is the managing director of Oncology GP LLC. Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.50 to $32.42 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"The shares are held as follows: 2,082,002 by BV 2014, 138,985 by MPM BioVentures 2014(B), L.P. (\"BV 2014(B)\"), 71,662 by AM BV2014, 1,314,948 by BV 2018, 69,951 by MPM BioVentures 2018(B), L.P. (\"BV 2018(B)\"), 25,951 by AM BV2018 and 2,353,426 by UBS Oncology.  Each of the Reporting Persons disclaims beneficial ownership of the securities herein except to the extent of his or its respective pecuniary interest therein, if any."}],"balance_after":6056925,"source":{"system":"sec-edgar","filing":"0001209191-21-026256","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000120919121026256/doc4.xml","form_type":"4"}},{"id":2907248,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series C Convertible Preferred Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":649030,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":649030},"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907247,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Convertible Preferred Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":2276692,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2276692},"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907246,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Convertible Preferred Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":3551640,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3551640},"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907245,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series Seed Convertible Preferred Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":false,"shares":1136525,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1136525},"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907244,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"purchase","acquired":true,"shares":300000,"price":21,"value":6300000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On January 12, 2021, OIF purchased 300,000 shares of Common Stock of the Issuer at a price of $21.00 per share pursuant to the Issuer's initial public offering."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7913887,"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907243,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":649030,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":7613887,"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907242,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":2276692,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":6964857,"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907241,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":3551640,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":4688165,"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":2907240,"issuer":{"id":4766,"kind":"organization","name":"Cullinan Therapeutics, Inc.","symbol":"CGEM"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-01-14T22:54:00.000Z","date":"2021-01-12","kind":"exercise","acquired":true,"shares":1136525,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series Seed Preferred Stock, Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred Stock (the \"Preferred Stock\") converted into shares of the Issuer's Common Stock on a 1-for-1 basis automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These securities are owned directly by UBS Oncology Impact Fund LP (\"OIF\"). The general partner of OIF is Oncology Impact Fund (Cayman) Management L.P. (\"OIF GP\"). The general partner of OIF GP is MPM Oncology Impact Management L.P. The general partner of MPM Oncology Impact Management L.P. is MPM Oncology Impact Management GP LLC. Dr. Ansbert Gadicke is a member of the Issuer's board of directors and is a managing member and the managing director of MPM Oncology Impact Management GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Each of the Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":1136525,"source":{"system":"sec-edgar","filing":"0000899243-21-002081","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000089924321002081/doc4.xml","form_type":"4"}},{"id":3010084,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-10-08T22:26:12.000Z","date":"2020-10-06","kind":"exercise","acquired":false,"shares":700453,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":700453},"source":{"system":"sec-edgar","filing":"0001209191-20-054320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919120054320/doc4.xml","form_type":"4"}},{"id":3010083,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A-1 Preferred Stock","published_at":"2020-10-08T22:26:12.000Z","date":"2020-10-06","kind":"exercise","acquired":false,"shares":1525348,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1525348},"source":{"system":"sec-edgar","filing":"0001209191-20-054320","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919120054320/doc4.xml","form_type":"4"}},{"id":3010082,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-08T22:26:12.000Z","date":"2020-10-06","kind":"purchase","acquired":true,"shares":151224,"price":15,"value":2268360.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":2377025,"source":{"system":"sec-edgar","filing":"0001209191-20-054320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919120054320/doc4.xml","form_type":"4"}},{"id":3010081,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-08T22:26:12.000Z","date":"2020-10-06","kind":"exercise","acquired":true,"shares":700453,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":2225801,"source":{"system":"sec-edgar","filing":"0001209191-20-054320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919120054320/doc4.xml","form_type":"4"}},{"id":3010080,"issuer":{"id":112213,"kind":"organization","name":"Oncorus, Inc.","symbol":"ONCR"},"owners":[{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":1,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":2,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-10-08T22:26:12.000Z","date":"2020-10-06","kind":"exercise","acquired":true,"shares":1525348,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of Series A-1 Preferred and Series B Preferred Stock automatically converted into shares of Common Stock upon the closing of the\nIssuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The reported securities are held in the account of UBS Oncology Impact Fund L.P. (\"UBS Oncology\"). MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing member of Oncology GP LLC."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The Reporting Persons disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein."}],"balance_after":1525348,"source":{"system":"sec-edgar","filing":"0001209191-20-054320","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1691428/000120919120054320/doc4.xml","form_type":"4"}},{"id":3073503,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":2600628,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":797983},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":35,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073502,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":29440,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":9033},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":34,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073501,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":79281,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24326},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":33,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073500,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":1491666,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":457706},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":32,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073499,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":81295,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":24944},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":31,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073498,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":157529,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48336},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073497,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B-2 Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":2361805,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F13","text":"Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":724702},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073496,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":4211330,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F12","text":"These securities are owned directly by UBS Oncology. MPM Oncology Impact Management GP LLC (\"Oncology GP LLC\") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology. Ansbert Gadicke is the managing director of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1397574},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073495,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":47674,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"These securities are owned directly by MPM Asset Management Investors BV 2018 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":15820},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073494,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":128384,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F10","text":"These securities are owned directly by MPM Bio Ventures 2018 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":42605},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073493,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":2415530,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F9","text":"These securities are owned directly by MPM Bio Ventures 2018 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":801619},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073492,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":131645,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F8","text":"These securities are owned directly by MPM Asset Management Investors BV 2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":43687},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073491,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":255094,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"These securities are owned directly by MPM Bio Ventures 2014 (B) LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":84655},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073490,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Series B Preferred Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"exercise","acquired":false,"shares":3824591,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"shares","element":"transactionShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of Series B Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 1,269,230 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 84,655 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 43,687 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 801,619 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"(Continued From footnote 2) The shares of Series B Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 42,605 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 15,820 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B Convertible Preferred stock held by UBS Oncology Impact Fund LP will convert automatically into 1,397,574 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 LP will convert automatically into 724,702 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F4","text":"(Continued From footnote 3) The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2014 (B) LP will convert automatically into 48,336 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2014 LLC will convert automatically into 24,944 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 LP will convert automatically into 457,706 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MPM Bio Ventures 2018 (B) LP will convert automatically into 24,326 shares of Common Stock upon the closing of the Issuer's initial public offering."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F5","text":"(Continued From footnote 4) The shares of Series B-2 Convertible Preferred stock held by MPM Asset Management Investors BV 2018 LLC will convert automatically into 9,033 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by UBS Oncology Impact Fund LP (\"UBS Oncology\") will convert automatically into 797,983 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F6","text":"These securities are owned directly by MPM Bio Ventures 2014 LP. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein"}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1269230},"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073489,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":160000,"price":19,"value":3040000.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F20","text":"On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F20","text":"On July 28, 2020, UBS Oncology purchased 160,000 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":2355557,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073488,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":1121,"price":19,"value":21299.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F19","text":"On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F19","text":"On July 28, 2020, MPM Asset Management Investors BV 2018 LLC purchased 1,121 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":25974,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073487,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":3020,"price":19,"value":57380.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F18","text":"On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F18","text":"On July 28, 2020, MPM Bio Ventures 2018 (B) LP purchased 3,020 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":69951,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073486,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":56814,"price":19,"value":1079466.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F17","text":"On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F17","text":"On July 28, 2020, MPM Bio Ventures 2018 LP purchased 56,814 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":1316139,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073485,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":3096,"price":19,"value":58824.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F16","text":"On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F16","text":"On July 28, 2020, MPM Asset Management Investors BV 2014 LLC purchased 3,096 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":71727,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}},{"id":3073484,"issuer":{"id":75965,"kind":"organization","name":"iTeos Therapeutics, Inc.","symbol":"ITOS"},"owners":[{"id":2481,"kind":"person","name":"GADICKE ANSBERT","position":1,"cik":"0001134655","reported_name":"GADICKE ANSBERT","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":false}},{"id":72215,"kind":"organization","name":"UBS Oncology Impact Fund L.P.","position":2,"cik":"0001691428","reported_name":"UBS Oncology Impact Fund L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":136045,"kind":"organization","name":"MPM Oncology Impact Management GP LLC","position":3,"cik":"0001721035","reported_name":"MPM Oncology Impact Management GP LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72217,"kind":"organization","name":"MPM BIOIMPACT LLC","position":4,"cik":"0001687078","reported_name":"MPM Oncology Impact Management LP","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}},{"id":72216,"kind":"organization","name":"Oncology Impact Fund (Cayman) Management L.P.","position":5,"cik":"0001721036","reported_name":"Oncology Impact Fund (Cayman) Management L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"X*"}}],"security":"Common Stock","published_at":"2020-07-30T12:00:49.000Z","date":"2020-07-28","kind":"purchase","acquired":true,"shares":5994,"price":19,"value":113886.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F15","text":"On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"On July 28, 2020, MPM Bio Ventures 2014 (B) LP purchased 5,994 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering."}],"balance_after":138985,"source":{"system":"sec-edgar","filing":"0000899243-20-020725","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1134655/000089924320020725/doc4.xml","form_type":"4"}}],"next_cursor":"2020-07-30T12:00:49.000000Z,3073484"}